Inactive Instrument

Melinta Therapeutics Inc Stock price Nasdaq

Equities

US58549G1004

Biotechnology & Medical Research

Dynamic Chart
Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam CI
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id CI
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection) CI
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis CI
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet CI
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc CI
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ CI
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin) CI
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy CI
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021 CI
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer CI
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections CI
More news
Managers TitleAgeSince
Chief Executive Officer 48 20-08-02
Director of Finance/CFO - 21-06-30
Compliance Officer 45 -
Members of the board TitleAgeSince
Director/Board Member 55 20-04-19
Director/Board Member - 20-04-19
Director/Board Member - 20-04-19
More insiders
Melinta Therapeutics Inc is a United States-based commercial-stage antibiotics company. The Company's products include Vabomere, Orbactiv, Minocin for injection, and Baxdela. Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Vabomere is indicated for the treatment of patients over 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs). Minocin for injection is indicated for the treatment of infections due to susceptible isolates of designated microorganisms, including Acinetobacter species bacteria.
More about the company
  1. Stock
  2. Equities
  3. Stock Melinta Therapeutics, Inc.
  4. Stock Melinta Therapeutics Inc - Nasdaq